Lung Cancer Trial, Recruiting NCT07441941 Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07441941
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who are receiving a single-session type of targeted radiation treatment called stereotactic body radiation therapy (SBRT)
  • People with an early-stage lung cancer (non-small cell lung cancer, stages T1-2 N0 M0) or people with a small number of tumours that have spread to the lung from elsewhere (no more than 3 such tumours)
  • People whose tumour cannot be removed by surgery, or who have chosen not to have surgery
  • People whose tumour measures 3 cm or smaller
  • People whose tumour is located in an outer part of the lung, at a specific distance away from the central airways and lung wall (confirm with trial site for exact measurements)
  • People whose cancer has either been confirmed by a tissue sample (biopsy) or identified through scans such as a CT scan and PET scan
  • People with a general health and activity level rated between 0 and 2 on a standard medical scale, meaning they are able to carry out daily activities with little to no limitation
  • People who are willing and able to attend scheduled visits and follow the study procedures
  • People who have signed a written consent form agreeing to take part
  • People who are covered by a French health insurance plan

Who may not be able to join:

  • People whose tumour has grown into the lining of the lung (pleura) or the central chest area (mediastinum)
  • People who currently have a lung infection (pneumonia) or inflammation around the heart (pericarditis)
  • People who have previously had radiation treatment to the same area of the body being targeted in this trial
  • People who have received pre-treatment (such as chemotherapy before the main treatment) for their current cancer
  • People with substance use issues, or medical, psychological, or social circumstances that could affect their ability to take part or affect the study results
  • People who are under a legal guardianship or similar form of legal protection (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People who are currently taking part in another clinical trial, or who have done so within the last 30 days
  • People whose life expectancy is estimated to be less than 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pierre Boisselier, ICM Co. Ltd.

Phone: 0467613102

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Registry
ClinicalTrials.gov
Start date
14 January 2026
Est. completion
30 November 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Evaluate the global quality of life of single-fraction pulmonary stereotactic radiation therapy; Evaluate the global quality of life of single-fraction pulmonary stereotactic radiation therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov